2024-516929-31-00
Recruiting
Phase 2
Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY
Humanitas Mirasole S.p.A.8 sites in 1 country50 target enrollmentStarted: October 21, 2024Last updated:
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Humanitas Mirasole S.p.A.
- Enrollment
- 50
- Locations
- 8
- Primary Endpoint
- Overall response rate (ORR) defined as patients in achieving a best overall response of complete response (CR) or partial response (PR) to study treatment, according to the 2014 Lugano Classification
Overview
Brief Summary
Assess the efficacy of loncastuximab tesirine as measured by overall response rate (ORR) in DLBCL and HGBCL patients failing CAR-T cell therapy
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female, aged ≥18 years.
- •Willing and able to give written, informed consent.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to
- •Histologically confirmed DLBCL or large B cell lymphoma (at last relapse) as defined by the 2016 WHO classification, including one of the following: • DLBCL, Not Otherwise Specified (NOS) • Transformed DLBCL from indolent lymphoma • HGBCL with MYC and BCL2 and/or BCL6 rearrangements (double/triple hit)
- •Patients failing CAR T-cell therapy, defined as: a. Progressive disease (PD) at any time b. Partial Remission (PR) or stable disease (SD) at 3 months after CAR T-cell infusion.
- •Measurable disease as defined by the 2014 Lugano Classification as assessed by positron-emission tomography (PET)- computed tomography (CT) or by CT or MRI if tumour is not FDG-avid on screening PET-CT.
- •Previous treatment with loncastuximab tesirine is allowed, provided that the patient was in CR or PR at the time of drug withdrawal.
- •Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test within 7 days prior to start of study drug (C1D1) for women of childbearing potential.
- •Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 9 months after the last dose of loncastuximab tesirine. Men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least 6 months after the patient receives his last dose of loncastuximab tesirine.
- •Adequate renal, hepatic, pulmonary, and cardiac function defined as: • Creatinine clearance ≥40 ml/min. • Serum alanine aminotransferase / aspartate aminotransferase ≤2.5 x ULN. • Total bilirubin ≤1.5 x ULN, except in subjects with Gilbert's syndrome. • Known history of LVEF ≥50% unless the institutional lower limit of normal is lower. • Baseline oxygen saturation >92% on room air and ≤Grade 1 dyspnoea.
Exclusion Criteria
- •Known history of hypersensitivity to or positive serum human antidrug antibody (ADA) to a CD19 antibody.
- •Females who are pregnant or lactating.
- •Active second primary malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's medical monitor and Investigator agree and document should not be exclusionary.
- •Lymphoma with active CNS involvement at the time of screening, including leptomeningeal disease.
- •Bulky disease, defined as largest tumour diameter >10 cm.
- •Known seropositive and requiring anti-viral therapy for human immunodeficiency (HIV) virus, hepatitis B virus (HBV), or hepatitis C virus (HCV).
- •Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
- •Significant medical comorbidities, including but not limited to, uncontrolled hypertension (blood pressure ≥160/100 mm Hg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 6 months prior to screening, uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes, or severe chronic pulmonary disease.
- •Active autoimmune disease, motor neuropathy considered of autoimmune origin, and other central nervous system (CNS) autoimmune disease.
- •History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
Outcomes
Primary Outcomes
Overall response rate (ORR) defined as patients in achieving a best overall response of complete response (CR) or partial response (PR) to study treatment, according to the 2014 Lugano Classification
Overall response rate (ORR) defined as patients in achieving a best overall response of complete response (CR) or partial response (PR) to study treatment, according to the 2014 Lugano Classification
Secondary Outcomes
- • Progression-free survival (PFS) defined as the time between first dose administration and the first documentation of recurrence or progression by independent central review, or death • Overall survival (OS) defined as the time between first dose administration and death from any cause • Duration of Response (DOR) defined as the time from first documentation of response to recurrence or progression by independent central review, or death
- • Frequency and severity of adverse events (AEs) and severeserious adverse events (SAEs)
- Exploratory • Relationship between blood serum markers of disease and inflammation (LDH, CRP, ferritin) and selected efficacy endpoints • Relationship between changes in plasma ctDNA and selected efficacy endpoints
Investigators
Michele Lagioia
Scientific
Humanitas Mirasole S.p.A.
Study Sites (8)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS 5)2023-503916-33-00ADC Therapeutics S.A.277
Not yet recruiting
Not Applicable
Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 InhibitorsNCT07258108Sun Yat-sen University35
Completed
Phase 2
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)2022-501601-12-00ADC Therapeutics S.A., ADC Therapeutics S.A.28
Active, not recruiting
Phase 4
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy2023-509738-20-00AbbVie Deutschland GmbH & Co. KG150
Recruiting
Phase 2
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyNCT07257055M.D. Anderson Cancer Center30